| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 1,571 | 1,664 | 1,697 | 1,783 | 1,839 | 2,038 | 1,967 | 2,121 | 2,104 | 2,273 | 2,365 | 2,484 | 2,583 |
| Expenses | 1,261 | 1,337 | 1,381 | 1,460 | 1,479 | 1,621 | 1,608 | 1,724 | 1,687 | 1,794 | 1,909 | 1,990 | 2,048 |
| EBITDA | 311 | 327 | 316 | 323 | 360 | 417 | 359 | 397 | 417 | 479 | 456 | 494 | 535 |
| Operating Profit % | 19 % | 20 % | 17 % | 18 % | 19 % | 19 % | 18 % | 19 % | 20 % | 21 % | 19 % | 19 % | 21 % |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 100 | 105 | 105 | 106 | 110 |
| Interest | 52 | 59 | 61 | 66 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 |
| Profit Before Tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 |
| Tax | 50 | 52 | 51 | 46 | 55 | 72 | 74 | 63 | 76 | 90 | 82 | 97 | 101 |
| Net Profit | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 293 |
| EPS in ₹ | 7.21 | 7.70 | 6.27 | 6.36 | 7.95 | 10.23 | 8.12 | 9.97 | 10.92 | 12.85 | 12.16 | 12.84 | 15.50 |
Emcure Pharmaceuticals
Emcure Pharmaceuticals
2,009.30
+5.50
(0.27%)
Market Cap
38,108.29 Cr
PE Ratio
37.53
Volume
1,69,313.00
Day High - Low
2,045.00 - 1,997.00
52W High-Low
2,100.70 - 1,260.00
Key Fundamentals
Market Cap
38,108.29 Cr
EPS
48.77
PE Ratio
37.53
PB Ratio
7.73
Book Value
260.93
EBITDA
1,877.20
Dividend Yield
0.18 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
18.91
Debt to Equity
0.27
Analyst Rating and Forecast
- By Refinitiv from9 analysts
Actual
Company News
View All News
Emcure Pharmaceuticals declared a final dividend of ₹3.60 per share for FY26 at its 45th AGM. The meeting also saw the reappointment of Satish Mehta as MD and the retirement of Chairman Berjis Desai.
Emcure Pharma to meet analysts and investors on Sep 4Sep 01, 2026
Emcure Pharmaceuticals has scheduled a meeting with analysts and investors on September 4. The engagement signals the company's intent to communicate directly with the investment community.
Emcure Pharmaceuticals releases FY26 BRSR report
Aug 28, 2026
Aug 28, 2026Emcure Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report for FY26. The filing details environmental metrics, employee safety data, and governance disclosures as per SEBI regulations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,868.90 | #1 4,48,411.71 | 36.35 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 45.40 | |
9,410.50 | 2,49,819.21 | 85.02 | 11,067.00 | 13.95 | 2,568 | 65.50 | 63.85 | |
4,970.00 | 1,89,042.82 | 84.76 | 13,886.20 | 20.34 | 2,138 | 3.28 | 53.46 | |
1,161.00 | 1,16,823.77 | 25.04 | 27,657.90 | 17.64 | 5,026 | -34.90 | 55.92 | |
1,386.10 | 1,11,975.44 | 33.02 | 29,044.60 | 2.24 | 3,870 | -39.18 | 45.81 | |
2,017.50 | 1,08,916.07 | 96.89 | 6,867.80 | 22.01 | 890 | #1 123.93 | 68.40 | |
2,437.80 | 1,00,680.16 | 46.30 | 14,636.40 | 14.85 | 1,938 | 29.13 | 59.36 | |
1,198.30 | 1,00,018.39 | 30.71 | 35,058.60 | 3.90 | 4,158 | -69.10 | 58.61 | |
1,713.40 | 98,585.25 | 26.90 | 34,145.20 | 5.56 | 3,503 | 25.21 | 59.22 | |
2,124.50 | 97,139.05 | #1 17.67 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 43.92 |
Growth Rate
Revenue Growth
17.14 %
Net Income Growth
33.05 %
Cash Flow Change
10.78 %
ROE
24.08 %
ROCE
21.73 %
EBITDA Margin (Avg.)
3.93 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 5,247 | 5,644 | 6,004 | 6,807 | 6,064 | 6,673 | 7,806 | 8,233 | 9,613 |
| Fixed Assets | 2,049 | 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,197 | 3,319 |
| Current Assets | 2,335 | 2,453 | 2,703 | 3,718 | 3,424 | 3,836 | 4,260 | 4,556 | 5,612 |
| Capital Work in Progress | 531 | 581 | 485 | 302 | 320 | 411 | 159 | 177 | 273 |
| Investments | 0 | 0 | 0 | 0 | 25 | 25 | 318 | 95 | 20 |
| Other Assets | 2,667 | 2,817 | 3,137 | 4,318 | 3,674 | 4,089 | 4,204 | 4,763 | 6,001 |
| Total Equity & Liabilities | 5,247 | 5,644 | 6,004 | 6,807 | 6,064 | 6,673 | 7,806 | 8,233 | 9,613 |
| Current Liabilities | 2,336 | 2,543 | 2,920 | 3,408 | 2,965 | 3,019 | 3,211 | 2,668 | 3,912 |
| Non Current Liabilities | 1,157 | 1,201 | 1,100 | 1,031 | 985 | 1,004 | 1,474 | 923 | 724 |
| Total Equity | 1,755 | 1,900 | 1,984 | 2,368 | 2,114 | 2,650 | 3,122 | 4,642 | 4,977 |
| Reserve & Surplus | 1,520 | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 4,257 | 4,760 |
| Share Capital | 181 | 181 | 181 | 181 | 181 | 181 | 181 | 190 | 190 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 | -58 | 112 |
| Investing Activities | -409 | -168 | -257 | -575 | -468 | -715 | -96 | -1,175 |
| Operating Activities | 444 | 500 | 704 | 768 | 747 | 1,097 | 852 | 944 |
| Financing Activities | -735 | -301 | -189 | -152 | -145 | -164 | -814 | 343 |
Share Holding
| % Holding | Jul 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 78.08 % | 78.08 % | 77.94 % | 77.92 % | 77.91 % | 77.88 % | 77.87 % | 77.87 % | 77.83 % |
| FIIs | 1.76 % | 2.91 % | 3.05 % | 3.07 % | 2.86 % | 3.29 % | 3.59 % | 3.35 % | 4.88 % |
| DIIs | 3.34 % | 3.96 % | 3.87 % | 3.44 % | 2.84 % | 4.37 % | 6.10 % | 6.10 % | 8.46 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.73 % | 5.00 % | 5.14 % | 5.51 % | 5.95 % | 6.24 % | 6.46 % | 6.46 % | 6.45 % |
| Others | 9.10 % | 10.04 % | 10.00 % | 10.06 % | 10.44 % | 8.22 % | 5.98 % | 6.22 % | 2.38 % |
| No of Share Holders | 4,98,006 | 1,52,914 | 1,43,449 | 1,39,671 | 1,33,549 | 1,26,169 | 1,18,863 | 1,22,189 | 1,24,991 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 3 | 3.6 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.19 | 0.18 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Sept 2026 |  Annual General Meeting | NA | 21 Sept 2026 | 1,878.40 | 2,015.75 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 1,406.40 | 1,444.25 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 1,345.75 | 1,249.80 |
| 22 May 2025 | Quarterly Result Announcement | NA | 22 May 2025 | 1,036.35 | 1,073.60 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 1,405.55 | 1,421.25 |
| 14 Aug 2025 |  Dividend | ₹ 3.00 /share | 14 Aug 2025 | 1,073.60 | 1,453.80 |
| 28 Aug 2025 | Annual General Meeting | NA | 28 Aug 2025 | 1,408.15 | 1,468.60 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 1,318.00 | 1,426.60 |
| 04 Feb 2026 | Quarterly Result Announcement | NA | 04 Feb 2026 | 1,557.90 | 1,505.75 |
| 05 May 2026 | Quarterly Result Announcement | NA | 05 May 2026 | 1,636.30 | 1,785.15 |
| 06 Aug 2026 | Quarterly Result Announcement | NA | 06 Aug 2026 | 1,810.10 | 1,959.00 |
| 04 Sept 2026 | Dividend | ₹ 3.60 /share | 04 Sept 2026 | 1,785.15 | 1,858.10 |
Announcements
Shareholder Meeting / Postal Ballot-Outcome of AGM12 hrs ago
12 hrs agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS10 days ago
10 days agoIntimation Under Regulations 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 01, 2026
Sep 01, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 01, 2026
Sep 01, 2026Announcement under Regulation 30 (LODR)-Credit RatingSep 01, 2026
Sep 01, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2026
Aug 29, 2026Business Responsibility and Sustainability Reporting (BRSR)Aug 28, 2026
Aug 28, 2026Notice Of The 45Th Annual General MeetingAug 28, 2026
Aug 28, 2026Reg. 34 (1) Annual Report.Aug 28, 2026
Aug 28, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 25, 2026
Aug 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2026
Aug 12, 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 08, 2026
Aug 08, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 06, 2026
Aug 06, 2026Intimation Of Date Of The 45Th Annual General Meeting And Record DateAug 06, 2026
Aug 06, 2026Announcement under Regulation 30 (LODR)-Change in ManagementAug 06, 2026
Aug 06, 2026Announcement under Regulation 30 (LODR)-Investor PresentationAug 06, 2026
Aug 06, 2026Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026Aug 06, 2026
Aug 06, 2026Board Meeting Outcome for Outcome Of Board Meeting Held On August 06 2026Aug 06, 2026
Aug 06, 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Completion Of Acquisition Of Shares Of Gennova Biopharmaceuticals Limited.
Jul 22, 2026
Jul 22, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJul 21, 2026
Jul 21, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 20, 2026
Jul 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2026
Jul 15, 2026Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026Jul 15, 2026
Jul 15, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 13, 2026
Jul 13, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 13, 2026
Jul 13, 2026Announcement under Regulation 30 (LODR)-RestructuringJul 11, 2026
Jul 11, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2026
Jul 07, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 03, 2026
Jul 03, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJun 30, 2026
Jun 30, 2026Closure of Trading WindowJun 29, 2026
Jun 29, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 19, 2026
Jun 19, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJun 12, 2026
Jun 12, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 27, 2026
May 27, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Inspection At Our Formulations Facility Located At Sanand Ahmedabad Gujarat India.May 16, 2026
May 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 11, 2026
May 11, 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingMay 08, 2026
May 08, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2026
May 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 05, 2026
May 05, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 05, 2026
May 05, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 62.09
ATR(14)
Volatile 63.99
STOCH(9,6)
Neutral 65.25
STOCH RSI(14)
Neutral 54.06
MACD(12,26)
Bullish 8.13
ADX(14)
Weak Trend 19.41
UO(9)
Bearish 45.91
ROC(12)
Uptrend And Accelerating 8.55
WillR(14)
Neutral -36.47
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes...more
Listing Date
10 Jul, 2024(2 Years, 2 Months, 12 Days)
Website
Chairperson NameSATISH RAMANLAL MEHTA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
